Highly active antiretroviral therapy (HAART) has been successful in delaying the progression to AIDS in HIV-1-infected individuals. Exposure to HAART can result in metabolic side effects, such as dyslipidemia, in a subset of recipients. Longitudinal data and frozen peripheral blood mononuclear cell pellets were obtained from 1,945 men enrolled in the Multicenter AIDS Cohort. Individuals were genotyped for ancestry informative markers (AIMs) and stratified by biogeographical ancestry (BGA). Then serum levels of total cholesterol (TCHOL), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TRIG) were examined controlling for a number of HIV and HAART-related covariates using multivariate mixed-effects linear regression. HIV-1 infection, in the absence of HAART, was associated with altered lipid levels for all phenotypes tested when compared to HIV-negative men. HIV-1-infected men receiving HAART also had significantly different lipid levels compared to HIV-negative men, except for LDL-C. There were statistically significant interactions between BGA and HIV/HAART status for all lipids tested. BGA remained significantly associated with lipid levels after controlling for other HIV and HAART-related covariates. There was low concordance between self-reported race (SRR) and BGA in admixed populations. BGA performed better than SRR in our statistical models. Lipid profiles in untreated HIV-1-positive men and HIV-1-positive men receiving HAART differ from HIV-negative men and this effect varies by BGA. BGA performed better in our statistical analysis as a racial classifier but SRR remains a good clinical surrogate for BGA.
Get full access to this article
View all access options for this article.
References
1.
GrunfeldC, PangM, DoerrlerWet al.Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab, 1992; 74,5:1045–1052.
2.
SafrinS, GrunfeldC. Fat distribution and metabolic changes in patients with HIV infection. AIDS, 1999; 13,18:2493–2505.
3.
Shor-PosnerG, BasitA, LuYet al.Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med, 1993; 94,5:515–519.
4.
El-SadrWM, MullinCM, CarrAet al.Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naive cohort. HIV Med, 2005; 6,2:114–121.
5.
YamashitaTE, PhairJP, MuñozAet al.Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS, 2001; 15,6:735–746.
6.
BonnetF, SavèsM, DrozCet al.Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. J Acquir Immune Defic Syndr, 2000; 25,2:199–200.
7.
CarrA, SamarasK, BurtonSet al.A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998; 12,7:F51–58.
8.
PériardD, TelentiA, SudrePet al.Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation, 1999; 100,7:700–705.
9.
RiddlerSA, SmitE, ColeSRet al.Impact of HIV infection and HAART on serum lipids in men. JAMA, 2003; 289,22:2978–2982.
10.
RanganathanS, KernPA. The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J Endocrinol, 2002; 172,1:155–162.
11.
BrownTT, XuX, JohnMet al.Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: A substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther, 2009; 6:8.
12.
GalliM, RidolfoAL, GervasoniC. Cardiovascular disease risk factors in HIV-infected patients in the HAART era. Ann NY Acad Sci, 2001; 946:200–213.
13.
RiddlerSA, LiX, OtvosJet al.Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr, 2008; 48,3:281–288.
14.
BehrensG, DejamA, SchmidtHet al.Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS, 1999; 13,10:F63–70.
15.
RiddlerSA, LiX, ChuHet al.Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med, 2007; 8,5:280–287.
16.
HadiganC, MeigsJB, CorcoranCet al.Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis, 2001; 32,1:130–139.
17.
RickertsV, BrodtH, StaszewskiS, StilleW. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study. Eur J Med Res, 2000; 5,8:329–333.
18.
JütteA, SchwenkA, FranzenCet al.Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?AIDS, 1999; 13,13:1796–1797.
19.
BozzetteSA, AkeCF, TamHK, ChangSW, LouisTA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med, 2003; 348,8:702–710.
KingsleyLA, Cuervo-RojasJ, MuñozAet al.Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS, 2008; 22,13:1589–1599.
23.
SeabergEC, BenningL, SharrettARet al.Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke, 2010; 41,10:2163–2170.
24.
MangiliA, GerriorJ, TangAMet al.Risk of cardiovascular disease in a cohort of HIV-infected adults: A study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis, 2006; 43,11:1482–1489.
25.
FoulkesAS, WohlDA, FrankIet al.Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med, 2006; 3,3:e52.
26.
KumarPN, Rodriguez-FrenchA, ThompsonMAet al.A prospective, 96-week study of the impact of trizivir, combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: Effect of sex and ethnicity. HIV Med, 2006; 7,2:85–98.
27.
GibertCL, ShlayJC, SharmaSet al.Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive persons initiating antiretroviral therapy. J Aquir Immune Defic Syndr, 2009; 50,1:44–53.
28.
Míguez-BurbanoMJ, LewisJE, MalowR. Alcohol and race/ethnicity elicit different changes in lipid profiles in HIV-infected individuals receiving highly active antiretroviral therapy. J Assoc Nurses AIDS Care, 2009; 20,3:176–183.
29.
JohnsonJL, SlentzCA, DuschaBDet al.Gender and racial differences in lipoprotein subclass distributions: The STRRIDE study. Atherosclerosis, 2004; 176,2:371–377.
30.
KullerLH. Ethnic differences in atherosclerosis, cardiovascular disease and lipid metabolism. Curr Opin Lipidol, 2004; 15,2:109–113.
31.
AulchenkoYS, RipattiS, LindqvistIet al.Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet, 2009; 41,1:47–55.
32.
HelgadottirA, ThorleifssonG, MagnussonKPet al.The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet, 2008; 40,2:217–224.
33.
KathiresanS, MelanderO, GuiducciCet al.Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet, 2008; 40,2:189–197.
34.
KathiresanS, WillerCJ, PelosoGMet al.Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet, 2009; 41,1:56–65.
35.
MorabiaA, CayanisE, CostanzaMCet al.Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors. Hum Mol Genet, 2003; 12,21:2733–2743.
36.
Wellcome Trust Case Consortium:. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007; 447,7145:661–678.
37.
KosoyR, NassirR, TianCet al.Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat, 2009; 30,1:69–78.
38.
NassirR, KosoyR, TianCet al.An ancestry informative marker set for determining continental origin: Validation and extension using human genome diversity panels. BMC Genet, 2009; 10:39.
39.
LinsTC, VieiraRG, AbreuBSet al.Genetic heterogeneity of self-reported ancestry groups in an admixed Brazilian population. J Epidemiol, 2011; 21,4:240–245.
40.
KaslowRA, OstrowDG, DetelsRet al.The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol, 1987; 126,2:310–318.
41.
PLINK [computer program]. Version 1.07. Shaun Purcell. 2009.
42.
PurcellS, NealeB, Todd-BrownKet al.PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet, 2007; 81,3:559–575.
43.
R [computer program]. Version 2.14.1. The R Foundation for Statistical Computing. 2008.
44.
BucoloG, DavidH. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem, 1973; 19,5:476–482.
45.
RifaiN, IannottiE, DeAngelisK, LawT. Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method. Clin Chem, 1998; 44,6 Pt 1:1242–1250.
46.
WarnickGR, AlbersJJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res, 1978; 19,1:65–76.
47.
AllainCC, PoonLS, ChanCSG, RichmondW, FuPC. Enzymatic determination of total serum cholesterol. Clin Chem, 1974; 20,4:470.
48.
Anon.:. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Ann Intern Med, 1998; 128,12 Pt 2:1079–1100.
49.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Sevices. 2012 May 25, C-6. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
50.
STATA [computer program]. Version 12.1 StataCorp. 2011.
51.
DiversJ, ReddenDT, RiceKMet al.Comparing self-reported ethnicity to genetic background measures in the context of the Multi-Ethnic Study of Atherosclerosis (MESA)BMC Genet, 2011; 12,1:28.
52.
GrunfeldC. Dyslipidemia and its treatment in HIV infection. Top HIV Med, 2011; 18,3:112–118.
53.
YuanJ, GuoS, HallDet al.Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS, 2011; 25,10:1271–1280.
54.
MallalS, NolanD, WittCet al.Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002; 359,9308:727–732.
55.
BrownTT, LiX, ColeSRet al.Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS, 2005; 19,13:1375–1383.
56.
MarzocchettiA, SchwarzJ, Di GiambenedettoSet al.The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. AIDS Res Hum Retroviruses, 2011; 27,12:1299–1309.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
